南宫NG·28

    关于我们
    研发服务
    服务平台
    客户中心
    新闻资讯
    投资者关系
    人力资源
    EN
    ×
    EN

    • 业务咨询

      中国：

      Email: marketing@hbyfcc.com

      业务咨询专线：400-780-8018

      （仅限服务咨询，其他事宜请拨打川沙总部电话）

      川沙总部电话: +86 (21) 5859-1500

      海外：

      +1(781)535-1428(U.S.)

      0044 7790 816 954 (Europe)

      Email:marketing@medicilon.com
    在线留言×
    点击切换
    Customer Center
    客户中心

    研究人员开发了一种高特异性的CDC7抑制剂TAK-931作为临床肿瘤治疗剂，抗肿瘤药效研究通过南宫NG·28进行

    2023-07-05
    |
    访问量：

    44.png

    Cell division cycle 7 (CDC7) plays important roles in DNA replication. Researchers developed a highly specific CDC7 inhibitor, TAK-931, as a clinical cancer therapeutic agent. The antitumor efficacy studies in PDX models were performed at Medicilon. 

    Medicilon has established a complete evaluation system for preclinical anti-tumor efficacy, and has more than 200 different types of tumor efficacy models.

    Reference:

    Kenichi Iwai, A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery. Sci Adv. 2021 May 21;7(21):eabf0197. doi: 10.1126/sciadv.abf0197. 


    相关新闻
    ×
    搜索验证
    点击切换
    友情链接: